See more : Consus Real Estate AG (0W6K.L) Income Statement Analysis – Financial Results
Complete financial analysis of Beam Therapeutics Inc. (BEAM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Beam Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Zedge, Inc. (ZDGE) Income Statement Analysis – Financial Results
- Allcargo Gati Limited (ACLGATI.BO) Income Statement Analysis – Financial Results
- Scoobeez Global, Inc. (SCBZ) Income Statement Analysis – Financial Results
- National Grid plc (NNGF.DE) Income Statement Analysis – Financial Results
- Tenmaya Store Co., Ltd. (9846.T) Income Statement Analysis – Financial Results
Beam Therapeutics Inc. (BEAM)
About Beam Therapeutics Inc.
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 377.71M | 60.92M | 51.84M | 24.00K | 18.00K | 0.00 | 0.00 |
| Cost of Revenue | 437.38M | 22.58M | 16.44M | 103.18M | 5.41M | 650.00K | 11.00K |
| Gross Profit | -59.67M | 38.34M | 35.40M | -103.16M | -5.39M | -650.00K | -11.00K |
| Gross Profit Ratio | -15.80% | 62.94% | 68.29% | -429,812.50% | -29,938.89% | 0.00% | 0.00% |
| Research & Development | 437.38M | 311.59M | 387.09M | 103.18M | 54.62M | 33.87M | 5.86M |
| General & Administrative | 116.81M | 87.81M | 57.22M | 29.61M | 20.55M | 11.87M | 2.02M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 116.81M | 87.81M | 57.22M | 29.61M | 20.55M | 11.87M | 2.02M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -71.00K | -10.04M | 378.00K |
| Operating Expenses | 554.19M | 399.40M | 444.31M | 132.78M | 75.17M | 45.74M | 7.88M |
| Cost & Expenses | 554.19M | 399.40M | 444.31M | 132.78M | 75.17M | 45.74M | 7.88M |
| Interest Income | 0.00 | 15.30M | 9.00K | 1.57M | 2.49M | 292.00K | 0.00 |
| Interest Expense | 0.00 | 15.30M | 9.00K | 1.57M | 187.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 20.01M | 22.58M | 16.44M | 9.47M | 5.41M | 650.00K | 11.00K |
| EBITDA | -156.47M | -324.33M | -392.47M | -128.03M | -71.65M | -45.09M | -7.99M |
| EBITDA Ratio | -41.43% | -659.03% | -799.13% | -269,270.83% | -384,644.44% | 0.00% | 0.00% |
| Operating Income | -176.49M | -338.48M | -392.47M | -132.76M | -75.15M | -45.74M | -7.88M |
| Operating Income Ratio | -46.73% | -555.61% | -757.01% | -553,166.67% | -417,522.22% | 0.00% | 0.00% |
| Total Other Income/Expenses | 45.32M | 78.30M | 21.83M | -61.83M | -3.17M | -71.00M | -122.00K |
| Income Before Tax | -131.16M | -260.18M | -370.64M | -194.59M | -78.33M | -116.74M | -8.00M |
| Income Before Tax Ratio | -34.73% | -427.08% | -714.91% | -810,800.00% | -435,144.44% | 0.00% | 0.00% |
| Income Tax Expense | 1.37M | 3.41M | -29.28M | 61.83M | 116.00K | -71.00M | 500.00K |
| Net Income | -132.53M | -263.59M | -341.36M | -256.42M | -78.44M | -115.26M | -8.00M |
| Net Income Ratio | -35.09% | -432.68% | -658.44% | -1,068,433.33% | -435,788.89% | 0.00% | 0.00% |
| EPS | -1.72 | -3.76 | -5.31 | -5.49 | -1.53 | -3.28 | -0.62 |
| EPS Diluted | -1.72 | -3.76 | -5.31 | -5.49 | -1.53 | -3.28 | -0.62 |
| Weighted Avg Shares Out | 77.15M | 70.02M | 64.23M | 46.73M | 51.34M | 35.14M | 12.95M |
| Weighted Avg Shares Out (Dil) | 77.15M | 70.02M | 64.23M | 46.73M | 51.34M | 35.14M | 12.95M |
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer
Why Is Beam Therapeutics (BEAM) Down 2.3% Since Last Earnings Report?
Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference
Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch
Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates
Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call Transcript
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates
Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs
Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting
Source: https://incomestatements.info
Category: Stock Reports